Cargando…

Comparative Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-analysis

Objective This network meta-analysis (NMA) assesses the clinical comparative efficacy and safety of sulodexide versus direct-acting oral anticoagulants (DOACs), vitamin K antagonist (VKA), and aspirin in patients with an unprovoked venous thromboembolism (VTE). Methods We conducted a literature se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pompilio, Giuseppe, Integlia, Davide, Raffetto, Joseph, Palareti, Gualtiero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188513/ https://www.ncbi.nlm.nih.gov/pubmed/32355907 http://dx.doi.org/10.1055/s-0040-1709731

Ejemplares similares

Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Andreozzi, Giuseppe M., et al.
Publicado: (2015)

Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism
por: Palareti, Gualtiero, et al.
Publicado: (2020)

Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It
por: Palareti, Gualtiero
Publicado: (2012)

Sulodexide for Secondary Prevention of Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis
por: Jiang, Qing-Jun, et al.
Publicado: (2018)

Cost‐minimization analysis of venous thromboembolism diagnosis: Comparison of standalone imaging with a strategy incorporating D‐dimer for exclusion of venous thromboembolism
por: Verma, Karan, et al.
Publicado: (2017)

Sulodexide in the Treatment of Early Stages of COVID-19
por: Gonzalez-Ochoa, Alejandro, et al.
Publicado: (2021)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

D-dimer levels during and after anticoagulation withdrawal in patients with venous thromboembolism treated with non-vitamin K anticoagulants
por: Legnani, Cristina, et al.
Publicado: (2019)

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
por: de Winter, Maria A, et al.
Publicado: (2023)

Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project
por: Bortoluzzi, Cristiano, et al.
Publicado: (2022)

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis
por: Khan, Faizan, et al.
Publicado: (2019)

Anticoagulation Duration After First Venous Thromboembolism: Real-Life Data From the International, Observational WHITE Study
por: Palareti, Gualtiero, et al.
Publicado: (2021)

Extended anticoagulation after venous thromboembolism: should it be done?
por: Fernandes, Caio J., et al.
Publicado: (2019)

Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism
por: Park, Haesuk, et al.
Publicado: (2022)

Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register
por: Palareti, Gualtiero, et al.
Publicado: (2021)

Costo per responder del metotrexato rispetto ad altre terapie in pazienti con psoriasi a placche da moderata a grave in Italia
por: Pompilio, Giuseppe, et al.
Publicado: (2022)

Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?
por: Weitz, Jeffrey I., et al.
Publicado: (2020)

Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis
por: Migliore, Alberto, et al.
Publicado: (2021)

Unprovoked or provoked venous thromboembolism: not the prevalent criterion to decide on anticoagulation extension in clinical practice of various countries—the prospective, international, observational WHITE study
por: Palareti, Gualtiero, et al.
Publicado: (2021)

Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis
por: Khan, Faizan, et al.
Publicado: (2017)

Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register
por: Palareti, Gualtiero, et al.
Publicado: (2020)

COVID-19 pandemic affects the ability of negative D-dimer to identify venous thromboembolism patients at low risk of recurrence: insights from the Apidulcis study
por: Palareti, Gualtiero, et al.
Publicado: (2022)

Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project
por: Bernardi, Enrico, et al.
Publicado: (2022)

Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer
por: Streiff, Michael B., et al.
Publicado: (2018)

Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism
por: Kang, Hye‐Rim, et al.
Publicado: (2023)

Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis
por: Mai, Vicky, et al.
Publicado: (2019)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2023)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

New anticoagulants for the treatment of venous thromboembolism
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2016)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants
por: Geldhof, Vincent, et al.
Publicado: (2014)

The renoprotective effects of sulodexide
por: Olde Engberink, Rik HG, et al.
Publicado: (2016)

D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study
por: Palareti, Gualtiero, et al.
Publicado: (2022)

P1641: RECURRENT VENOUS THROMBOEMBOLISMS AND ANTICOAGULATION COMPLICATIONS; A PROSPECTIVE STUDY.
por: Nasibov, Teymur, et al.
Publicado: (2023)

Budget Impact di afatinib per il trattamento in prima linea del Non Small Cell Lung Cancer (NSCLC) con mutazioni non comuni EGFR
por: Pompilio, Giuseppe, et al.
Publicado: (2022)

Efficacy and Safety of Direct Oral Anticoagulants for Risk of Cancer-Associated Venous Thromboembolism
por: Zeng, Jie, et al.
Publicado: (2019)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: McRae, Simon J, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_73apflajsrl65de4upom3qa9ua